PASTEUR Act of 2026
Summary
The PASTEUR Act of 2026 (HR7352) is in early legislative stages — referred to two House committees. It authorizes a new subscription contract program for innovative antimicrobial drugs to combat antibiotic-resistant pathogens. No specific funding amount is appropriated, and the bill remains far from potential enactment. Near-term market impact is low as no pure-play publicly traded company is directly positioned to capture revenue from this nascent program.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7352 is an early-stage authorization bill with no appropriated funding, meaning no near-term revenue impact for any company.
- 2.The bill creates a subscription contract mechanism for antimicrobials, but the contracting entity and specific budget remain undefined.
- 3.No public company is identifiable as a direct beneficiary — private biotech firms likely would be the first applicants.
- 4.Bipartisan sponsorship and a Senate companion exist, increasing medium-term passage probability but not near-term market impact.
Market Implications
The near-term market implications are negligible. The antimicrobial resistance (AMR) space lacks publicly traded pure-play developers of sufficient scale to be directly impacted by this early-stage authorization. Large-cap pharma ($PFE, $MRK) derive less than 1% of revenue from antibiotics; the bill's mechanism is too nascent to affect their near-term financials. If appropriations materialize, small-cap biotechs in late-stage antimicrobial development could be structural beneficiaries, but no current publicly traded company clearly qualifies. Investors monitoring AMR should watch committee markups and budget resolutions for future catalysts.
Full Analysis
On February 4, 2026, Representative Buddy Carter (R-GA) introduced the PASTEUR Act of 2026 (HR7352) in the House. It has been referred to both the Energy and Commerce Committee and the Budget Committee — a standard early-stage procedural step for an authorization bill. The bill proposes to amend the Public Health Service Act to create a novel subscription-based procurement program (U.S. NOVEL ANTIMICROBIAL SUPPLY CONTRACTS) where the Secretary of Health and Human Services can enter into contracts with sponsors of eligible antimicrobial drugs that treat urgent/serious antibiotic-resistant pathogens and address unmet medical needs. This is an authorization-only bill — it sets policy and a contracting framework but includes no specific dollar figure for appropriations. Actual funding would require separate appropriations legislation. The legislative path is long: after committee markups, it must pass both chambers and be signed by The President. The companion identical bill (S4875) in the Senate has been referred to the Health, Education, Labor, and Pensions Committee, indicating bipartisan interest but early-stage activity. The convergence with the Senate companion is direct — they share the same objective and text. However, no pure-play publicly traded company is specifically positioned to benefit as a direct contract winner under this program at this stage. The antimicrobial development space is dominated by smaller private biotech firms and large diversified pharma companies where antimicrobial revenue is a negligible fraction of total sales. Major pharma companies ($PFE, $MRK, $GSK, $AZN) have exited or de-emphasized antibiotic R&D — this bill aims to rescue that broken market but has not yet appropriated funds or created near-term revenue. For a retail investor, the signal is a policy tailwind that is far from implemented. Impact score of 3 reflects early procedural stage, absence of appropriated funding, and lack of clear publicly traded beneficiaries.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL: $123M Department of Health and Human Services Contract
A bill to amend the Public Health Service Act to establish a program to develop innovative antimicrobial drugs targeting the most challenging pathogens and most threatening infections, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →